New Heart Drugs More Expensive than Expected
Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much July 27, 2015 | By Ben Hirschler LONDON (Reuters) - Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much. Praluent (alirocumab) injection, made by Sanofi and Regeneron Pharmaceuticals, and Entresto (sacubitril/valsartan) from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. But their positioning in the marketplace was always likely to be contentious since they offer more effective alternatives to very cheap, off-patent drugs. The manufacturers have taken an ambitious view on pricing, arguing that the clear medical benefits of their products and their ability to keep patients out of ...
Comments
Post a Comment